(Q48902538)

16 February 2018

title

How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. (English)

1 reference

16 February 2018

4

Dhananjay Pal

1 reference

16 February 2018

author name string

Vibhuti Agrahari

1

1 reference

16 February 2018

Vivek Agrahari

2

1 reference

16 February 2018

Abhirup Mandal

3

1 reference

16 February 2018

Ashim K Mitra

5

1 reference

16 February 2018

language of work or name

English

0 references

publication date

14 December 2016

1 reference

16 February 2018

Expert Opinion on Drug Delivery

published in

1 reference

16 February 2018

volume

14

1 reference

16 February 2018

issue

10

1 reference

16 February 2018

page(s)

1145-1162

1 reference

16 February 2018

Ocular delivery of macromolecules

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Drug discovery in ophthalmology: past success, present challenges, and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Current advances in the treatment of neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Nanomedicines for back of the eye drug delivery, gene delivery, and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Nanotherapy for posterior eye diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

New techniques for drug delivery to the posterior eye segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Advanced drug delivery and targeting technologies for the ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Drug delivery to the back of the eye following topical administration: an update on research and patenting activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Modern drug delivery systems for targeting the posterior segment of the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Ocular drug delivery systems: An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Transporter effects on cell permeability in drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Drug and gene delivery to the back of the eye: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Composite Nanoformulation Therapeutics for Long-Term Ocular Delivery of Macromolecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

The suprachoroidal pathway: a new drug delivery route to the back of the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Advances in ocular drug delivery: emphasis on the posterior segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Stem cell based therapies for age-related macular degeneration: The promises and the challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Immunology of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Oxidative stress, innate immunity, and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Emerging treatments for wet age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Anti-VEGF agents for age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Pegaptanib for the treatment of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Novel delivery approaches for cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Synthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic Acid conjugate with a hydrolyzable schiff base spacer for treating retinal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Dexamethasone nanowafer as an effective therapy for dry eye disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Ocular drug delivery nanowafer with enhanced therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Liposomes for intravitreal drug delivery: a state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Liposome: classification, preparation, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Controlled ocular drug delivery with nanomicelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Hydrogels in a historical perspective: from simple networks to smart materials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Biodegradable implants for sustained drug release in the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Intraocular implants for extended drug delivery: therapeutic applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Drug delivery to the posterior segment of the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Drug delivery implants in the treatment of vitreous inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

A passive MEMS drug delivery pump for treatment of ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Minimally invasive microneedles for ocular drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Microneedle-based minimally-invasive measurement of puncture resistance and fracture toughness of sclera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Sustained, Controlled and Stimuli-Responsive Drug Release Systems Based on Nanoporous Anodic Alumina with Layer-by-Layer Polyelectrolyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Ophthalmic light sensitive nanocarrier systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Thermoresponsive polymers: insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

In situ gel systems as 'smart' carriers for sustained ocular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system: preparation, characterization, and in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Toxicity evaluation of biodegradable and thermosensitive PEG-PCL-PEG hydrogel as a potential in situ sustained ophthalmic drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Ultrasound-mediated ocular delivery of therapeutic agents: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Ultrasound-enhanced ocular delivery of dexamethasone sodium phosphate: an in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Electrochemically controlled drug delivery based on intrinsically conducting polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

A refillable microfabricated drug delivery device for treatment of ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Consequences of oxidative stress in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Reactive Oxygen Species (ROS) Responsive Polymers for Biomedical Applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Stem cell treatment of degenerative eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Stem cells as source for retinal pigment epithelium transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Age-Related Macular Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Stem Cell Sources and Their Potential for the Treatment of Retinal Degenerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Stem cells in clinical trials for treatment of retinal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Cell-Based Therapy for Degenerative Retinal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous redifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Development of human embryonic stem cell therapies for age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Approaches to cell delivery: substrates and scaffolds for cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Impaired RPE survival on aged submacular human Bruch's membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

A novel Bruch's membrane-mimetic electrospun substrate scaffold for human retinal pigment epithelium cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

The cultivation of human retinal pigment epithelial cells on Bombyx mori silk fibroin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Encapsulated cell therapy for neurodegenerative diseases: from promise to product

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Application of encapsulated cell technology for retinal degenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Design and in vitro biocompatibility of a novel ocular drug delivery device

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

Therapeutic cell encapsulation: ten steps towards clinical translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425247.2017.1272569

10.1080/17425247.2017.1272569

21 January 2018

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018